Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
NCT00083083
Unknown
RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2011
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Lung Cancer
Register for Updates
Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
NCT00191139
Completed
To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2010
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Memphis, Tennessee
Conditions: Non-small Cell Lung Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00053105
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effect of combination chemotherapy on the body when treating patients who have relapsed or refractory aggressive non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
07/04/2009
Locations: Boston Baskin Cancer Group, University Tennessee, Memphis, Tennessee
Conditions: Lymphoma
Register for Updates
Therapy for Children With Advanced Stage High Risk Neuroblastoma
NCT00186849
Completed
This is a Phase II pilot study of chemotherapy and surgery for children with advanced stage high-risk neuroblastoma utilizing topotecan during an upfront window and other active agents during induction and intensification phases. The primary purpose is to estimate the response rate to an upfront window of two cycles of intravenous topotecan. We hypothesize that the topotecan window will be an effective therapy in terms of the response rate.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
05/19/2009
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma
Register for Updates
CPG 7909 Injection in Non-Small Cell Lung Cancer
NCT00070629
Completed
Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone. Protocol therapy will be administered until disease progression or intolerable toxicity. CpG 7909 Injection will be administered subcutaneously, on Weeks 2 and 3 of each three-week cycle (days 8 and 15) and chemotherapy will be administered on Week 1 (Day 1). Patients will undergo complete disease evaluation at the end of every ot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2009
Locations: The Family Cancer Center, Collierville, Tennessee
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates
Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors
NCT00116896
Completed
This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2009
Locations: Vanderbilt Universtiy Medical Center, Nashville, Tennessee
Conditions: Advanced Solid Tumors
Register for Updates
Therapy for Children With Neuroblastoma
NCT00135135
Completed
This is a phase II window study of the combination of ZD1839 (gefitinib) and irinotecan in children with high-risk neuroblastoma followed by standard induction chemotherapy, intensification with autologous stem cell transplantation, and an oral maintenance phase with 13-cis-retinoic acid and topotecan. We hypothesize that the ZD1839 (gefitinib) and irinotecan window will be efficacious.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
06/02/2008
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma
Register for Updates